SELECT trial full breakdown: semaglutide, cardiovascular death, and the longevity question

RAPAMYCIN MODERATE ▲ +3 papers · 7d METFORMIN MODERATE ▲ +1 paper · 7d NMN EMERGING ▲ +6 papers · 7d NR EMERGING ▲ +2 papers · 7d D + Q EMERGING ▲ +12 papers · 7d GLP-1 AGONISTS STRONG ▲ +7 papers · 7d SGLT2 INHIBITORS STRONG ACARBOSE MODERATE TAURINE EMERGING BERBERINE EMERGING 17Α-ESTRADIOL EMERGING SPERMIDINE EMERGING ▲ +2 papers · 7d UROLITHIN A EMERGING ▲ +1 paper · 7d FISETIN EMERGING GLYNAC EMERGING RAPAMYCIN MODERATE ▲ +3 papers · 7d METFORMIN MODERATE ▲ +1 paper · 7d NMN EMERGING ▲ +6 papers · 7d NR EMERGING ▲ +2 papers · 7d D + Q EMERGING ▲ +12 papers · 7d GLP-1 AGONISTS STRONG ▲ +7 papers · 7d SGLT2 INHIBITORS STRONG ACARBOSE MODERATE TAURINE EMERGING BERBERINE EMERGING 17Α-ESTRADIOL EMERGING SPERMIDINE EMERGING ▲ +2 papers · 7d UROLITHIN A EMERGING ▲ +1 paper · 7d FISETIN EMERGING GLYNAC EMERGING

§ Overview

SELECT showed semaglutide reduced major adverse cardiovascular events in non-diabetic obese adults — the first GLP-1 outcome trial in this population. Full breakdown for longevity medicine.

Evidence tier: Strong. Drug class: GLP-1 receptor agonist. This profile synthesizes the published human trial evidence. The full profile with all indexed papers, active trial alerts, and tier history is available to subscribers.

§ Key human evidence

RCT

SELECT — New England Journal of Medicine, 2023

n=17,604

Non-diabetic adults with BMI ≥27 and established CVD. Weekly semaglutide 2.4mg versus placebo for median 34 months. Primary MACE: HR 0.80 (95% CI 0.72–0.90). CV death HR 0.85 (not statistically significant individually but directionally consistent). Non-fatal MI HR 0.72 (p<0.001). Non-fatal stroke HR 0.93 (p=0.20). This is the first randomized trial to demonstrate cardiovascular benefit of any drug in non-diabetic individuals classified by obesity.

Mechanism uncertainty

SELECT mechanism analyses, 2024

n=17,604

Weight loss explains approximately 40–50% of the cardiovascular risk reduction in SELECT analyses. The remainder may reflect anti-inflammatory effects, direct cardiac effects, or other mechanisms. The implication is that semaglutide's CV benefit is not purely a weight-loss drug effect — though separation of weight-dependent and weight-independent mechanisms in practice is difficult.

Longevity medicine implications

SELECT in the longevity context

n=17,604

SELECT established semaglutide as a cardiovascular medicine in non-diabetic obese adults — the most directly longevity-relevant GLP-1 outcome data to date. For longevity medicine practitioners, the key question is whether cardiovascular risk reduction will translate to all-cause mortality benefit in longer follow-up, and whether similar benefits apply to overweight adults with BMI 25–27 who fall below the SELECT enrollment threshold.

§ The honest clinical position

Every Geroevidence profile ends with an honest assessment of what the evidence supports and what it does not. This intervention is rated Strong based on the published human trial evidence indexed above.

The full honest clinical assessment — including evidence tier rationale, key limitations, and what trials would be needed to upgrade the tier — is in the subscriber profile. The summary: the mechanistic basis is coherent and human trial data is available; the specific clinical applications and limitations are detailed in the full profile.

This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.

Full evidence profile

All indexed papers · active trials · daily alerts

Start free trial →

14 DAYS FREE · NO CARD REQUIRED

Top interventions by evidence

GLP-1 agonists

CV outcome trials · SELECT

mTOR inhibitor · PEARL

Moderate View all interventions →